An Investigation Into the Nanosuspension of Candesartan Cilexetil, a Drug With Limited Solubility

The Biopharmaceutical Classification System (BSC) classifies Candesartan Cilexetil as a class II medication due to its low solubility and bioavailability. Candesartan Cilexetil nanosuspensions were made using antisolvent precipitation-ultrasonication and an alternate solvent. Drug solubility has improved with this method. The antisolvent volume is 1:15. Candesartan cilexetil nanosuspension was stabilised with PVP K-30. The Plackett-Burman design identified the main nanosuspension quality, stability, and efficiency element. The study examined mean particle size, saturation solubility, zeta potential, polydispersity index (PDI), cumulative percentage released (CPR) at two minutes, and percent weighted drug content using a 32-factorial design. We calculated the saturation solubility (µg/mL) and particle size (nm) of candesartan cilexetil nanosuspension batch CFD8 using mean ± standard deviation. Calculations showed values of 240.7 ± 8.3 and 113.03 ± 2.51. In vitro dissolution was performed on the unmilled suspension and commercial formulation.